Metabolic reprogramming and metabolic rewiring have been used to describe the metabolic alterations in cancer cells where bioenergetics, anabolic biosynthesis and appropriate redox status are coordinated to promote cell proliferation and tumor growth. We believe that metabolic reprogramming represents software changes in cancer cells and describes metabolic alterations normally induced by growth factors in proliferative cells that are hijacked by oncogenic signals, whereas metabolic rewiring represents hardware changes in cancer cells and describes metabolic alterations that are newly forged due to neo-function of distinct oncogenic mutants, but not found in normal cells. Although increasing evidence emerges and suggests that different human cancers may share common metabolic properties, such as the Warburg effect, it is not clear whether distinct oncogene mutations, including oncogenes as well as tumor suppressor genes (TSGs), in different cancer types may require different metabolic properties for tumor development, and thus specifically rewire and reprogram cancer cell metabolism. We approached to this question by identifying unique metabolic vulnerability required by oncogenic BRAF V600E mutant in human melanoma cells, which are not required by other oncogenes such as NRas Q61R/K. We found that HMG-CoA lyase (HMGCL), a key enzyme in ketogenesis producing ketone bodies, is a synthetic lethal partner of BRAF V600E. HMGCL expression is upregulated in BRAF V600E-expressing human primary melanoma and hairy cell leukaemia cells in tissue samples from patients. Suppression of HMGCL specifically attenuates proliferation and tumor growth potential of human melanoma cells expressing BRAF V600E. Mechanistically, HMGCL controls the intracellular levels of its product, acetoacetate, to promote activation of MEK-ERK signaling, where acetoacetate specifically enhances binding of BRAF V600E but not BRAF wild type to MEK. We also found that BRAF V600E may phosphorylate and activate a transcription factor Oct-1 to upregulate HMGCL in a MEK1-ERK independent manner. Moreover, a high-fat diet resulted in increased serum levels of acetoacetate but selectively promoted tumor formation of BRAF V600E-expressing melanoma cells in mice. Thus, we hypothesize that oncogenic BRAF V600E rewires metabolic and cell signaling networks and signals through Oct-1 to promote the HMGCL-acetoacetate axis that selectively enhances BRAF V600E-dependent tumor development.
Three Specific Aims : (1) To determine whether a ketogenic diet (high-fat and low carbohydrate) would worsen the disease burden in diverse BRAF V600E-positive mouse models with melanoma or hairy cell leukemia; (2) To validate the HMGCL-acetoacetate axis as an alternative therapeutic target in treatment of BRAF V600E-positive human malignancies; (3) To elucidate the molecular mechanisms by which acetoacetate specifically promotes BRAF V600E-MEK1 binding, and active forms of BRAF including V600E mutant activate Oct-1.

Public Health Relevance

Cancer cells appear to coordinate bioenergetics (aerobic glycolysis), anabolic biosynthesis and appropriate redox status to promote cancer cell proliferation and tumor growth. In this proposal, we plan to explore the molecular mechanisms by which oncogenic BRAF V600E 'rewires' metabolic and cell signaling networks and signals through transcription factor Oct-1 to promote the HMGCL-acetoacetate axis that selectively enhances BRAF V600E-dependent tumor development. The HMGCL-acetoacetate axis thus needs to be taken into consideration regarding cancer prevention and clinical treatment of BRAF V600E-expressing human malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA140515-06A1
Application #
8964020
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Watson, Joanna M
Project Start
2010-02-23
Project End
2020-07-31
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
6
Fiscal Year
2015
Total Cost
$387,250
Indirect Cost
$135,152
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Zhao, Liang; Fan, Jun; Xia, Siyuan et al. (2017) HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. J Biol Chem 292:10142-10152
Elf, S; Lin, R; Xia, S et al. (2017) Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisinin. Oncogene 36:254-262
Zhang, Ye; Xu, Ying-Ying; Yao, Chuan-Bo et al. (2017) Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone. Autophagy 13:538-553
Xia, Siyuan; Lin, Ruiting; Jin, Lingtao et al. (2017) Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. Cell Metab 25:358-373
Fan, Jun; Lin, Ruiting; Xia, Siyuan et al. (2016) Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth. Mol Cell 64:859-874
Lin, Ruiting; Elf, Shannon; Shan, Changliang et al. (2015) 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol 17:1484-96
Jin, Lingtao; Li, Dan; Alesi, Gina N et al. (2015) Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell 27:257-70
Wang, Jing; Luo, Cheng; Shan, Changliang et al. (2015) Inhibition of human copper trafficking by a small molecule significantly attenuates cancer cell proliferation. Nat Chem 7:968-79
Kang, Hee-Bum; Fan, Jun; Lin, Ruiting et al. (2015) Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. Mol Cell 59:345-358
Hitosugi, T; Chen, J (2014) Post-translational modifications and the Warburg effect. Oncogene 33:4279-85

Showing the most recent 10 out of 21 publications